Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020011869 - OLIGONUCLÉOTIDES ANTISENS CIBLANT TLR2

Numéro de publication WO/2020/011869
Date de publication 16.01.2020
N° de la demande internationale PCT/EP2019/068571
Date du dépôt international 10.07.2019
CIB
C12N 15/113 2010.01
CCHIMIE; MÉTALLURGIE
12BIOCHIMIE; BIÈRE; SPIRITUEUX; VIN; VINAIGRE; MICROBIOLOGIE; ENZYMOLOGIE; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE
NMICRO-ORGANISMES OU ENZYMES; COMPOSITIONS LES CONTENANT; CULTURE OU CONSERVATION DE MICRO-ORGANISMES; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE; MILIEUX DE CULTURE
15Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
09Technologie d'ADN recombinant
11Fragments d'ADN ou d'ARN; Leurs formes modifiées
113Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
CPC
C12N 15/1138
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
1138against receptors or cell surface proteins
C12N 2310/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
10Type of nucleic acid
11Antisense
C12N 2310/315
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
31of the backbone
315Phosphorothioates
C12N 2310/3231
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
32of the sugar
323modified ring structure
3231having an additional ring, e.g. LNA, ENA
C12N 2310/3341
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
33of the base
334Modified C
33415-Methylcytosine
C12N 2310/341
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
34Spatial arrangement of the modifications
341Gapmers, i.e. of the type ===---===
Déposants
  • ROCHE INNOVATION CENTER COPENHAGEN A/S [DK]/[DK]
Inventeurs
  • LINDHOLM, Eva Marie
  • SCHMIDT, Steffen
Mandataires
  • ALTMANN STÖSSEL DICK PATENTANWÄLTE PARTG MBB
Données relatives à la priorité
18182902.911.07.2018EP
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) ANTISENSE OLIGONUCLEOTIDES TARGETING TLR2
(FR) OLIGONUCLÉOTIDES ANTISENS CIBLANT TLR2
Abrégé
(EN)
The present invention relates to antisense LNA oligonucleotides (oligomers) complementary to TLR2 pre-mRNA exon sequences, which are capable of inhibiting the expression of TLR2 protein. Inhibition of TLR2 expression is beneficial for a range of medical disorders including of lupus erythematosus, such as systemic lupus erythematosus (SLE), rheumatoid arthritis, asthma, psoriasis, renal ischemia/reperfusion injury, sepsis, lung disease, atherosclerosis, hypertension, myocardial infarction, stroke, Alzheimer's disease and cerebrovascular injury.
(FR)
La présente invention concerne des oligonucléotides (oligomères) LNA antisens complémentaires des séquences d'exon pré-ARNm de TLR2, qui sont capables d'inhiber l'expression de la protéine TLR2. L'inhibition de l'expression de TLR2 est bénéfique pour une gamme de troubles médicaux comprenant le lupus érythémateux, notamment le lupus érythémateux disséminé (SLE), la polyarthrite rhumatoïde, l'asthme, le psoriasis, l'ischémie rénale/lésion de reperfusion, la sepsie, la maladie pulmonaire, l'athérosclérose, l'hypertension, l'infarctus du myocarde, l'accident vasculaire cérébral, la maladie d'Alzheimer et la lésion cérébrovasculaire.
Dernières données bibliographiques dont dispose le Bureau international